Solid biosciences announces licensing agreement with kinea bio for the use of proprietary next-generation capsid aav-slb101

- non-exclusive license for solid's proprietary, next generation capsid, aav-slb101, to accelerate development of kinea bio's gene therapy for dysferlin-related limb-girdle muscular dystrophy -

SLB Ratings Summary

SLB Quant Ranking